Literature DB >> 30538778

Successful Localization Using 68Ga-DOTATOC PET/CT of a Phosphaturic Mesenchymal Tumor Causing Osteomalacia in a Patient with Concurrent Follicular Lymphoma.

Sejin Ha1, Sujin Park1, Hyunji Kim1, Heounjeong Go2, Seung Hun Lee3, Ji Yoon Choi4, Jung Yong Hong5, Jin-Sook Ryu1.   

Abstract

Diagnosing tumor-induced osteomalacia is often challenging because conventional imaging modalities may fail to locate the responsible tumor. This report describes the ability of 68Ga-DOTATOC PET/CT to successfully distinguish between the responsible phosphaturic mesenchymal tumor and concurrent lymphoma lesions. A 52-year-old man with bone pain for several years was diagnosed with a vitamin D-resistant hypophosphatemic osteomalacia. Whole body 18F-FDG PET/CT revealed multiple enlarged hypermetabolic lymph nodes in his bilateral cervical, axillary, mediastinal, abdominal, pelvic, and inguinal regions. Core needle biopsy of the right cervical lymph node confirmed the diagnosis of follicular lymphoma. However, lymphoma was not considered the cause of osteomalacia. 68Ga-DOTATOC PET/CT before chemotherapy showed a small nodule with intensely increased uptake in the right inguinal region, which was distinguished from the other enlarged lymph nodes. The nodule was surgically removed and histopathologically consistent with phosphaturic mesenchymal tumor. After surgery, the patient's serum phosphorus and alkaline phosphatase levels normalized without nutritional supplement.

Entities:  

Keywords:  68Ga-DOTATOC; Hypophosphatemia; Oncogenic osteomalacia; PET/CT; Phosphaturic mesenchymal tumor

Year:  2018        PMID: 30538778      PMCID: PMC6261860          DOI: 10.1007/s13139-018-0546-5

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  33 in total

1.  Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

Authors:  Matthias Miederer; Stefan Seidl; Andreas Buck; Klemens Scheidhauer; Hans-Jürgen Wester; Markus Schwaiger; Aurel Perren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-20       Impact factor: 9.236

2.  Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT.

Authors:  Roderick J Clifton-Bligh; Michael S Hofman; Emma Duncan; Ie-Wen Sim; David Darnell; Adele Clarkson; Tricia Wong; John P Walsh; Anthony J Gill; Peter R Ebeling; Rodney J Hicks
Journal:  J Clin Endocrinol Metab       Date:  2013-01-07       Impact factor: 5.958

Review 3.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 4.  Hypophosphatemia: an update on its etiology and treatment.

Authors:  André Gaasbeek; A Edo Meinders
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

5.  Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients.

Authors:  Swati Jadhav; Rajeev Kasaliwal; Vikram Lele; Venkatesh Rangarajan; Piyush Chandra; Hina Shah; Gaurav Malhotra; Varsha S Jagtap; Sweta Budyal; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-12       Impact factor: 3.478

6.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.

Authors:  Michael S Hofman; W F Eddie Lau; Rodney J Hicks
Journal:  Radiographics       Date:  2015 Mar-Apr       Impact factor: 5.333

7.  Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets.

Authors:  N Weidner; D Santa Cruz
Journal:  Cancer       Date:  1987-04-15       Impact factor: 6.860

8.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Authors:  Michelle Houang; Adele Clarkson; Loretta Sioson; Marianne S Elston; Roderick J Clifton-Bligh; Michael Dray; Dominique Ranchere-Vince; Anne-Valerie Decouvelaere; Arnaud de la Fouchardiere; Anthony J Gill
Journal:  Hum Pathol       Date:  2013-09-20       Impact factor: 3.466

9.  Severe hypophosphatemia in a general hospital population.

Authors:  A L King; D A Sica; G Miller; S Pierpaoli
Journal:  South Med J       Date:  1987-07       Impact factor: 0.954

10.  Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.

Authors:  Qing-Yao Zuo; Hong Wang; Wei Li; Xiao-Hui Niu; Yan-Hong Huang; Jia Chen; Yu-Hua You; Bao-Yue Liu; Ai-Min Cui; Wei Deng
Journal:  BMC Musculoskelet Disord       Date:  2017-09-21       Impact factor: 2.362

View more
  5 in total

1.  Phosphaturic Mesenchymal Tumor.

Authors:  J C Benson; J A Trejo-Lopez; A M Nassiri; K Eschbacher; M J Link; C L Driscoll; R D Tiegs; J Sfeir; D R DeLone
Journal:  AJNR Am J Neuroradiol       Date:  2022-05-19       Impact factor: 4.966

2.  Extended Whole-body Ga-68 DOTATATE PET-CT in evaluating Tumour-Induced Osteomalacia: Case report and review of literature.

Authors:  Teik Hin Tan; Ew-Jun Chen; Ming Tsuey Chew; Ping Ching Chye; Ming Wong
Journal:  Nucl Med Mol Imaging       Date:  2021-04-19

3.  Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia.

Authors:  Dong Yun Lee; Seung Hun Lee; Beom-Jun Kim; Wanlim Kim; Pil Whan Yoon; Sang Ju Lee; Seung Jun Oh; Jung-Min Koh; Jin-Sook Ryu
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

Review 4.  Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway.

Authors:  Mohsin A M Hussein; Francesco Pio Cafarelli; Maria Teresa Paparella; Winston J Rennie; Giuseppe Guglielmi
Journal:  Radiol Med       Date:  2021-08-28       Impact factor: 3.469

Review 5.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.